CompletedNot Applicable

The Clinical Study Aims to Assess the Quality of Donor Livers Using Hyperspectral Imaging.

China40 participantsStarted 2022-06-01

Plain-language summary

Based on hyperspectral imaging equipment, this project collected hyperspectral imaging data of donor livers, analyzed various parameters, investigated the detection capability of hyperspectral imaging for assessing donor liver quality, gathered patient prognosis information, examined the correlation between early postoperative complications and hyperspectral imaging data, and explored characteristic parameters for evaluating donor liver quality using hyperspectral imaging technology. The occurrence of early complications was predicted.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Recipients ranged in age from 18 to 65
✓. Donor age ≥ 18 years

Exclusion criteria

✕. Recipients are younger than 18 years or older than 65 years
✕. Donor younger than 18 years
✕. Secondary liver transplantation.
✕. Multiple organ transplantation.

What they're measuring

Hyperspectral imaging to assess ischemia-reperfusion injury in liver grafts

Timeframe: From June 1,2022 to June 30,2024

Trial details

NCT IDNCT06608667

SponsorFirst Affiliated Hospital Xi'an Jiaotong University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-12-30

View on ClinicalTrials.gov More Liver Transplantation trials